Jiangsu Hengrui Sets Detailed Mandate for Board Audit Committee

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an announcement.

Jiangsu Hengrui Pharmaceuticals has established an Audit Committee under its board of directors, defining a detailed mandate to strengthen corporate governance and oversight. The committee is tasked with pre-audit review, supervision of financial disclosure, and exercising supervisory powers normally held by a supervisory committee under Chinese company law.

The Audit Committee will be composed mainly of non-executive and independent directors with financial or legal expertise, including at least one accounting professional as chair. It is charged with overseeing the work, independence and remuneration of the external auditor, setting procedures for auditor appointment and removal, and ensuring regular, management-free meetings with the audit firm to discuss audit scope, fees and issues arising from the audit process.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$92.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company operating in the healthcare industry, with shares listed in Shanghai and Hong Kong. The company focuses on developing, manufacturing and marketing pharmaceutical products, and is subject to corporate governance and listing rules in both mainland China and Hong Kong.

Average Trading Volume: 3,328,521

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$420.7B

Learn more about 1276 stock on TipRanks’ Stock Analysis page.